Terlipressin plus Albumin for the Treatment of Type 1 Hepatorenal Syndrome.
Wong F, Pappas SC, Curry MP, Reddy KR, Rubin RA, Porayko MK, Gonzalez SA, Mumtaz K, Lim N, Simonetto DA, Sharma P, Sanyal AJ, Mayo MJ, Frederick RT, Escalante S, Jamil K; CONFIRM Study Investigators.
N Engl J Med. 2021 Mar 4;384(9):818-828. doi: 10.1056/NEJMoa2008290.
News in pathophysiology, definition and classification of hepatorenal syndrome: A step beyond the International Club of Ascites (ICA) consensus document.
Angeli P, Garcia-Tsao G, Nadim MK, Parikh CR.
J Hepatol. 2019 Oct;71(4):811-822. doi: 10.1016/j.jhep.2019.07.002. Epub 2019 Jul 11.
Management of hepatorenal syndrome in liver cirrhosis: a recent update.
Bera C, Wong F.
Therap Adv Gastroenterol. 2022 Jun 14;15:17562848221102679. doi: 10.1177/17562848221102679. eCollection 2022.
Evidence-based clinical practice guidelines for Liver Cirrhosis 2020.
Yoshiji H, Nagoshi S, Akahane T, Asaoka Y, Ueno Y, Ogawa K, Kawaguchi T, Kurosaki M, Sakaida I, Shimizu M, Taniai M, Terai S, Nishikawa H, Hiasa Y, Hidaka H, Miwa H, Chayama K, Enomoto N, Shimosegawa T, Takehara T, Koike K.
J Gastroenterol. 2021 Jul;56(7):593-619. doi: 10.1007/s00535-021-01788-x. Epub 2021 Jul 7.
Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failure.
Wong F, Pappas SC, Reddy KR, Vargas H, Curry MP, Sanyal A, Jamil K.
Aliment Pharmacol Ther. 2022 Oct;56(8):1284-1293. doi: 10.1111/apt.17195. Epub 2022 Aug 22.
Terlipressin given by continuous intravenous infusion versus intravenous boluses in the treatment of hepatorenal syndrome: A randomized controlled study.
Cavallin M, Piano S, Romano A, Fasolato S, Frigo AC, Benetti G, Gola E, Morando F, Stanco M, Rosi S, Sticca A, Cillo U, Angeli P.
Hepatology. 2016 Mar;63(3):983-92. doi: 10.1002/hep.28396. Epub 2016 Feb 3.
Hepatorenal syndrome.
Lata J.
World J Gastroenterol. 2012 Sep 28;18(36):4978-84. doi: 10.3748/wjg.v18.i36.4978.
Portal hypertension in cirrhosis: Pathophysiological mechanisms and therapy.
Iwakiri Y, Trebicka J.
JHEP Rep. 2021 Jun 4;3(4):100316. doi: 10.1016/j.jhepr.2021.100316. eCollection 2021 Aug.
The Comparative Effectiveness of Vasoactive Treatments for Hepatorenal Syndrome: A Systematic Review and Network Meta-Analysis.
Pitre T, Kiflen M, Helmeczi W, Dionne JC, Rewa O, Bagshaw SM, Needham-Nethercott N, Alhazzani W, Zeraatkar D, Rochwerg B.
Crit Care Med. 2022 Oct 1;50(10):1419-1429. doi: 10.1097/CCM.0000000000005595. Epub 2022 Sep 12.
Terlipressin and albumin combination treatment in patients with hepatorenal syndrome type 2.
Nguyen-Tat M, Jäger J, Rey JW, Nagel M, Labenz C, Wörns MA, Galle PR, Marquardt JU.
United European Gastroenterol J. 2019 May;7(4):529-537. doi: 10.1177/2050640619825719. Epub 2019 Feb 20.
